TH84864A - Antibody formula - Google Patents
Antibody formulaInfo
- Publication number
- TH84864A TH84864A TH501004920A TH0501004920A TH84864A TH 84864 A TH84864 A TH 84864A TH 501004920 A TH501004920 A TH 501004920A TH 0501004920 A TH0501004920 A TH 0501004920A TH 84864 A TH84864 A TH 84864A
- Authority
- TH
- Thailand
- Prior art keywords
- antibody
- antibodies
- formula
- histidine
- antibody formula
- Prior art date
Links
- 108090001123 antibodies Proteins 0.000 title claims abstract 12
- 102000004965 antibodies Human genes 0.000 title claims abstract 12
- HABAJMUFCIDFOT-JEDNCBNOSA-M (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid;acetate Chemical compound CC([O-])=O.OC(=O)[C@@H](N)CC1=CN=CN1 HABAJMUFCIDFOT-JEDNCBNOSA-M 0.000 claims abstract 4
- 239000008351 acetate buffer Substances 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- BZWQQOVSUSJJJO-QAGDRQIHSA-N 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione;hydrate Chemical compound O.O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BZWQQOVSUSJJJO-QAGDRQIHSA-N 0.000 abstract 2
- 102100016662 ERBB2 Human genes 0.000 abstract 2
- 101700025368 ERBB2 Proteins 0.000 abstract 2
- 101710037934 QRSL1 Proteins 0.000 abstract 2
- 108010048040 apomab Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010045030 monoclonal antibodies Proteins 0.000 abstract 2
- 102000005614 monoclonal antibodies Human genes 0.000 abstract 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 abstract 1
- 229960000060 monoclonal antibodies Drugs 0.000 abstract 1
Abstract
DC60 การประยุกต์ใช้ที่มีอยู่อธิบายถึงสูตรแอนติบอดีซึ่งประกอบด้วยแอนติบอดีชนิดโมโนโคลนัล ผลิตตามสูตรในบัฟเฟอร์ชนิดฮิสติดีน-อะซิเทตรวมไปถึงสูตรประกอบไปด้วยแอนติบอดีชนิดซึ่งเชื่อม ต่อเข้ากับโดเมน II ของ HER2 (ตัวอย่างเช่นเปอร์ทูซูแมบ) และสูตรประกอบไปด้วยแอนติบอดีชนิด ซึ่งเชื่อมต่อเข้ากับ DR5 (ตัวอย่างเช่นอะโพแมบ) การประยุกต์ใช้ที่มีอยู่อธิบายถึงสูตรแอนติบอดีซึ่งประกอบด้วยแอนติบอดีชนิดโมโนโคลนัล ผลิตตามสูตรในบัฟเฟอร์ชนิดฮิสติดีน-อะซิเทตรวมไปถึงสูตรประกอบไปด้วยแอนติบอดีชนิดซึ่งเชื่อม ต่อเข้ากับโดเมน II ของ HER2 (ตัวอย่างเช่นเปอร์ทูซูแมบ) และสูตรประกอบไปด้วยแอนติบอดีชนิด ซึ่งเชื่อมต่อเข้ากับ DR5 (ตัวอย่างเช่นอะโพแมบ) สิทธิบัตรยา DC60, an existing application describes an antibody formula consisting of a monoclonal antibody. It is formulated in histidine-acetate buffer, including the formulation of antibodies. It is attached to the domain II of HER2 (for example, supertosumab) and the formula contains antibodies. Which binds to DR5 (for example, apomab). Existing application describes an antibody formula consisting of monoclonal antibodies. It is formulated in histidine-acetate buffer, including the formulation of antibodies. It is attached to the domain II of HER2 (for example, supertosumab) and the formula contains antibodies. Which is connected to the DR5 (for example, apomab), drug patents
Claims (4)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH84864B TH84864B (en) | 2007-06-07 |
| TH84864A true TH84864A (en) | 2007-06-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2371388A3 (en) | Antibody formulations | |
| UA107557C2 (en) | OFATUMUMAB ANTIBODY COMPOSITION | |
| TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| NO20083895L (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| CL2010000426A1 (en) | Human antibody that binds to the ligand for human ox40 (ox40l or gp34); Method of production; and pharmaceutical composition that includes it (div. sol. n ° 2389-05). | |
| CL2012001966A1 (en) | Pharmaceutical formulation comprising between 100-150 mg / ml of an antibody that specifically binds to a human il-17 receptor, an aqueous solution of a 5-30 mm buffer of glutamic acid ph 4.5-5.2, proline 2-4% w / v and polysorbate-20 0.005-0.02% w / v; pharmaceutical package and kit comprising said formulation; and its use to treat psoriasis. | |
| EP1855719A4 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
| RU2009148286A (en) | LIQUID PHARMACEUTICAL COMPOSITION OF BOTULIN TOXIN | |
| EA200970469A1 (en) | ANTIBODY-AGONISTS OF THE TRKB RECEPTOR AND THEIR APPLICATION | |
| NO20071436L (en) | Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| IL195338A (en) | Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof | |
| MA30474B1 (en) | FORMULATIONS OF MOLECULE PEPTIDE (S) - LYOPHILIZED THERAPEUTIC ANTIBODY. | |
| ATE534667T1 (en) | ANTI-ABETA ANTIBODIES | |
| PA8782201A1 (en) | HUMANIZED ANTIBODY AGAINST AB GLOBULOMER (20-42) AND ITS USES | |
| EA200800952A1 (en) | CONJUGATES ANTIBODY-DRUG AND METHODS OF APPLICATION | |
| EA201201533A1 (en) | PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS | |
| NZ595694A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
| UA94628C2 (en) | Humanized monoclonal antibody that binds to steap-1 and use thereof | |
| WO2006033700A3 (en) | Her2 antibody composition | |
| EA200702375A1 (en) | UREA DERIVATIVES, METHODS FOR THEIR RECEPTION AND APPLICATION | |
| WO2009008414A1 (en) | Monoclonal antibody having neutralizing activity against mmp13 | |
| TH84864A (en) | Antibody formula | |
| TH84864B (en) | Antibody formula |